In March 2025, the company introduced new options for any direct-to-consumer offering of its Wegovy weight loss drug. The company established a brand new pharmacy, known as NovoCare, which might demand customers $499 each month for access to the drug, less than 50 percent the cost of the drug by way of other pharmaceutical distribution networks.[53